Biopharma earnings have come with pipeline rethinks, as Takeda, Regeneron, Sanofi, and Bristol Myers Squibb announced program cuts alongside their quarterly updates. The changes signal continued pruning of early-stage bets and a move toward tighter capital allocation as companies manage late-stage execution and shifting risk profiles. On the clinical development side, Takeda’s celiac disease pipeline narrowed further with another discontinuation in phase 2, dropping TAK-101 after the trial wrapped and the company said it assessed the program as not meeting expectations. The update leaves TAK-227 as the remaining celiac shot, underscoring how hard it has been to translate immune reprogramming approaches into durable clinical benefit. Sanofi’s operational reset also continues through R&D cleanup and ongoing portfolio decisions, with management looking to reverse setbacks and better align resources to late-stage priorities amid a patent cliff. Collectively, these moves reflect a sector-wide push toward fewer, higher-conviction bets.